We are proud to work together with our competent partner organizations:
PsykForsk works to promote research in psychiatry through clinical trials with novel psychotropic drugs and psychotherapy. In collaboration with partners in the pharmaceutical industry, PsykForsk tests the healing potential of various psychoactive substances such as ketamine, MDMA, and psilocybin in combination with talk therapy.
In the autumn of 2020, their department also established the first ketamine unit in the public health care sector in Norway. During the first year, they treated a large number of patients with therapy-resistant depression and with significant effect. In 2021, the team participated as the only testing site in the Nordic region in a Multidisciplinary Association for Psychedelic Studies (MAPS) study Phase 2, with MDMA-assisted psychotherapy for people with post traumatic stress disorder (PTSD). In 2022, they plan to carry out two international clinical multicenter studies in Phase 3.
The team is led by Dr. Ingmar Clausen, and is organized under District Psychiatric Center (DPS), Nordre Østfold in the clinic for mental health care, Østfold Hospital. Professor Ole Andreassen at NorMent and Oslo University Hospital (OUS) is closely associated with the team serving as Principal Investigator (PI) in current clinical trial studies.
The Network for Psychedelic Science (NPV) is a non-profit association based in Stockholm that works to promote a scientific exploration of psychedelic substances. NPV believes that there is a high potential for important applications in the psychological and medical field that justify further investigation. By informing and disseminating knowledge about this field of research, NPV intends to contribute to opportunities for scientific review of data and future development of new evidence-based methods.
The ALPS Foundation is a non-profit foundation based in Geneva, working to contribute to the continuing growth of psychedelic sciences in Switzerland. To achieve this, we aim our efforts towards building a sense of community, inform professionals and students, and create media content sharing evidence based information on the psychedelic field. Our most recent endeavor was the organization of the ALPS Conference this fall. We are happy to see the psychedelic field grow around the world, and so it is with great enthusiasm that we welcome the Nordic Psychedelic Science Conference.
ICPR 2022 is Europe’s pioneering and leading conference on psychedelic science and therapy, organised by the OPEN Foundation in Amsterdam since 2007. Paul Stamets, Katrin Preller, David Nutt, Erika Dyck, Roland Griffiths, Monnica Williams, David Nichols, and up to 100 speakers will discuss rigorous science, critical perspectives, and psychedelic therapies on September 22nd-24th, 2022.
OPEN has given us a special €100 discount code for our community! Use the code NPSC100 when checking out your tickets here: https://icpr-conference.com/tickets
We are lucky to be supported by some of the leading companies within psychedelic science today.
Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will deliver these evidence backed psychedelic therapies in clinics in the UK and Europe and through licensing partnerships globally.
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since its founding, MAPS has raised more than $117 million for psychedelic and marijuana research and education and has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator.
COMPASS is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. In November 2021, COMPASS announced positive topline results from the largest randomised, controlled, double-blind clinical trial of psilocybin therapy ever conducted.
Osmond Foundation is a Swedish non-profit organization founded in 2020, to facilitate the scientific understanding of psychedelics and their medical potential. It does so by providing help with strategy, funding and communication. Osmond Labs, a subsidiary of Osmond Foundation, provides regulatory expertise and GMP investigational drugs to qualified researchers. As the field of psychedelic science is opening up in Sweden and Europe, Osmond Foundation is a central node in the growing network of researchers and philanthropists wanting to make a contribution.
Viriditas foundation is an initiative that seeks to support the understanding, evolution and expansion of consciousness. The intention is to function as a catalyst for projects in the arts, sciences and humanities, which stimulate spiritual and social growth whilst promoting a sustainable and desirable future from a holistic perspective. Viriditas Foundation was founded in Stockholm, Sweden, in 2017 by playwright, director and psychotherapist Åsa Olsson in collaboration with current fellow board members Jonas Pettersson, clinical psychologist and musician, and David Österberg, psychotherapist and sound designer/composer.